Jaffe–Campanacci syndrome: Any role for 99mTc-methylene diphosphonate bone and 99mTc-octreotide scans for evaluation of the disorder?

Mohsen Qutbi; Sajad Ghanbari; Isa Neshandar Asli; Babak Shafiei

doi:10.4103/wjnm.wjnm_21_18

World Journal of Nuclear Medicine, Table of Contents

CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(02): 189-191
DOI: 10.4103/wjnm.wjnm_21_18

Case Report

Jaffe–Campanacci syndrome: Any role for ^99mTc-methylene diphosphonate bone and ^99mTc-octreotide scans for evaluation of the disorder?

Authors

Mohsen Qutbi

⁰Department of Nuclear Medicine, Taleghani Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Sajad Ghanbari

⁰Department of Nuclear Medicine, Taleghani Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Isa Neshandar Asli

⁰Department of Nuclear Medicine, Taleghani Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Babak Shafiei

⁰Department of Nuclear Medicine, Taleghani Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Jaffe–Campanacci syndrome (JCS) is a rare clinical disorder with almost unknown etiology. The main feature of this syndrome is skeletal involvement as nonossifying fibroma which may cause severe morbidity to these patients. X-ray imaging is the widely available modality for evaluation of skeleton, but radionuclide imaging modalities may have a role in workup. Herein, we present a case of JCS evaluated with ^99mTc-methylene diphosphonate bone and ^99mTc-octreotide scans for the extent of skeletal involvement. To the best of our knowledge, from over than 30 cases reported in the literature, no evaluation with radionuclide imaging has been done.

Keywords

Bone scan - Jaffe–Campanacci syndrome - octreotide scan

Full Text

References

References
1 Hau MA, Fox EJ, Cates JM, Brigman BE, Mankin HJ. Jaffe-campanacci syndrome. A case report and review of the literature. J Bone Joint Surg Am 2002;84-A:634-8.
2 Mankin HJ, Trahan CA, Fondren G, Mankin CJ. Non-ossifying fibroma, fibrous cortical defect and Jaffe-Campanacci syndrome: A biologic and clinical review. Chir Organi Mov 2009;93:1-7.
3 Cherix S, Bildé Y, Becce F, Letovanec I, Rüdiger HA. Multiple non-ossifying fibromas as a cause of pathological femoral fracture in Jaffe-Campanacci syndrome. BMC Musculoskelet Disord 2014;15:218.
4 Jaffe HL. Tumors and Tumorous Conditions of the Bones and Joints. London: Henry Kimpton; 1958. p. 83-91.
5 Campanacci M, Laus M, Boriani S. Multiple non-ossifying fibromata with extraskeletal anomalies: A new syndrome? J Bone Joint Surg Br 1983;65:627-32.
6 Mirra JM, Gold RH, Rand F. Disseminated nonossifying fibromas in association with café-au-lait spots (Jaffe-Campanacci syndrome). Clin Orthop Relat Res 1982;168:192-205.
7 Colby RS, Saul RA. Is Jaffe-Campanacci syndrome just a manifestation of neurofibromatosis type 1? Am J Med Genet A 2003;123A: 60-3.
8 Abdel-Wanis ME, Kawahara N. Skeletal disorders associated with skin pigmentation: A role of melatonin? Med Hypotheses 2003;61:640-2.
9 Stewart DR, Brems H, Gomes AG, Ruppert SL, Callens T, Williams J, et al. Jaffe-Campanacci syndrome, revisited: Detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. Genet Med 2014;16:448-59.
10 Sevencan A, İnan U, Köse N. A new syndrome mimicking Jaffe-Campanacci syndrome: A case report. Eklem Hastalik Cerrahisi 2013;24:46-8.